🇺🇸

IPO Capital Markets

US SEC Filing Intelligence · 164 digests

New to these filings? Learn what an S-1 is · what an S-3 shelf registration is

· daily

US IPO Pipeline SEC S-1 Filings — October 30, 2026

The October 30, 2026 IPO Pipeline filings reveal a bifurcated market: traditional IPO/SPAC registrations (Evernorth, D. Boral ARC, UCSB) proceed with structural filings but zero pricing or financial detail, while small-cap registrants (Capstone, Banzai, Mobix) disclose dilutive financing and distress. The sole M&A deal (First Financial/First Illinois) is a $111.3M bank merger with a downside equity adjustment, signaling cautious consolidation in community banking. Across the seven filings, no revenue or earnings data was provided, so period comparisons are impossible; instead, the enriched data highlights capital structure complexity, insider/sponsor activity, and event-driven catalysts. The most critical development is Capstone's uncured Event of Default on its 3i note, creating immediate foreclosure and dilution risk. SPAC activity (Armada II, D. Boral, UCSB) suggests a steady but opaque blank-check pipeline, with Armada II already executing a merger via Evernorth's S-1. Overall, the filings point to a market where new issue supply is rising but quality is uneven, with distressed small-caps and structured SPACs dominating the day's registrations.

7 high priority 7 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 29, 2026

The October 29, 2026 IPO pipeline is dominated by small-cap and micro-cap registrations, with three S-1 filings spanning a blank-check vehicle, a DFW stone fabricator, and a distressed resale registration. The common thread is governance and structural risk: Redwoods Acquisition Corp II offers a standard SPAC unit with 100% redemption and a 12-month clock, KAT Construction Services presents a dual-class structure where Series A preferred carries ~96.8% voting power despite raising only ~$20M, and La Rosa (now Stratum Holdings) registers up to 69.7M shares under a $1B equity line but expects only ~$30M in gross proceeds while flagging late 10-K/10-Q filings and a pivot to a single-lessee GPU leasing business. Period-over-period comparisons are largely unavailable in the enriched data, but the filings reveal a clear pattern of capital-structure complexity and disclosure gaps rather than operational momentum. Sentiment is neutral for the two new registrants and negative for La Rosa, with materiality scores of 6, 6, and 7 respectively. The absence of insider buying, dividends, or buybacks across all three filings underscores that these are capital-raising events, not shareholder-return stories. Investors should focus on deal terms, governance protections, and the credibility of forward-looking business pivots rather than near-term fundamentals.

3 high priority 3 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 28, 2026

This IPO Pipeline digest covers a single US SEC filing dated 2026-10-28: a Form S-4 registration statement from Graf Global Corp., a Cayman Islands blank-check company (SPAC), tied to a proposed business combination with Halfcourt Holdco, Inc., a Delaware sports and recreational clubs/promotion company (SIC 7941) based in Miami Beach. The filing is preliminary and unpriced, subject to a Business Combination Agreement and closing conditions, and the excerpt contains no target financial results, so period-over-period comparisons, guidance, insider activity, and capital allocation data are not available to quantify. The materiality score is 6/10 with neutral sentiment, reflecting a de-SPAC pathway that is a meaningful pipeline event but lacks the financial detail needed for conviction. Portfolio-level patterns cannot be drawn from a single filing, so the key takeaway is process-oriented: the deal's progress will be determined by the S-4 amendment cycle, shareholder vote, and any disclosed target financials that follow.

1 high priority 1 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 27, 2026

This IPO Pipeline stream covers seven SEC filings dated October 27, 2026, dominated by capital-raising registrations (S-1s) from distressed or thinly capitalized issuers rather than clean IPO candidates. Five of the seven filings carry negative or mixed sentiment with explicit going-concern, material-weakness, or no-minimum-proceeds language, and the excerpts provided contain few quantitative period-over-period results, so trend analysis is limited to what the filings disclose. The most material developments are Splash Beverage Group's dilution overhang (roughly 11.3M shares on preferred conversion plus a 20% RSU grant pending approval, against a stock range of $0.135 to $3.92 post reverse split) and Bionano Genomics' going-concern warning requiring significant financing within 12 months. Imunon's best-efforts raise has no minimum proceeds, and Aupenheim's $1.6M self-underwritten offering carries PRC-related regulatory risk. The Twin Vee/USFM merger (S-4) and the Heroic Empire blank-check SPAC (S-1) are the more structured transactions, with defined trust sizes, cross-conditioned votes, and lock-up terms. Portfolio-level pattern: capital is being raised on dilutive, contingent terms, and proceeds certainty is weak across the pipeline.

7 high priority 7 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 26, 2026

Six filings dated October 26, 2026 populate the US SEC IPO Pipeline stream, but the enriched period-over-period, insider, guidance and capital allocation fields are largely absent from the excerpts provided, so the synthesis is constrained to what the narrative text supports. The clearest IPO-pipeline activity is Anthropic's S-1 for a Nasdaq Global Select listing, which carries the highest materiality (8/10) because of a dual-class structure in which Class F stock gives the Founder LLC 50.1% of general voting power while economic interests are not proportionate, and a Long-Term Benefit Trust elects a board majority via Class T stock. LIS Technologies filed a firm-commitment IPO of 2,833,334 shares at an assumed $6.00 (range $5.00-$7.00) on Nasdaq Capital Market, led by Titan Partners, with no operating results in the excerpt to assess. Traws Pharma's S-1 is a resale registration tied to a $50M standby equity facility with Roth at a fixed 6.0% discount to VWAP, implying dilution risk for existing holders. First Tracks Biotherapeutics' S-1 covers a spin-off from AnaptysBio and shows a sharp decline in short-dated Treasury holdings from $249.0M (Dec 2024) to $63.3M (Dec 2025), a balance-sheet trend worth monitoring. Klotho/Greenland Mines and PUBLIC CO MANAGEMENT CORP are resale and business-combination registrations with limited narrative detail, so their investment read is largely procedural. Overall, the pipeline skews toward speculative small-cap listings and discounted equity lines rather than large, clearly priced offerings.

6 high priority 6 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 23, 2026

The IPO Pipeline stream for 2026-10-23 contains three SEC filings, and the enriched data supplied is thin: none of the three excerpts contains narrative financial figures, period-over-period comparisons, insider transactions, capital allocation detail, or forward-looking guidance that could support quantitative trend analysis. The dominant themes are SPAC-related and resale-driven capital markets activity rather than fresh IPO issuance. Alchemy Acquisition Holdings (ALCY) is a distressed SPAC that missed its 36-month business combination deadline, was suspended from Nasdaq on May 14, 2026, and trades on OTC Pink with no third-party valuation or fairness opinion supporting its pending Cartiga merger. Evernorth's S-1 is a registration whose embedded XBRL metadata relates to Armada Acquisition Corp. II, with XRP-linked subscription agreements, but the excerpt contains no verifiable dollar amounts. Onfolio (ONFO) is registering resale of up to 105.2 million shares under an equity line capped at $100 million, at a sub-$1 price, which signals meaningful dilution pressure. Because the underlying figures cannot be verified from the supplied content, conclusions below are directional and should be confirmed against the full filings before any position is taken.

3 high priority 3 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 22, 2026

Five SEC filings dated October 21-22, 2026 span IPO registrations (Rezera, TG-17, AlphaVest), a private-placement-style note offering (Phoenix Capital Group), and a small best-efforts follow-on (reAlpha). The most substantive quantitative picture comes from Rezera, a pre-revenue biotech whose six-month net loss widened 86% YoY to $25.5M, with R&D up ~93% and G&A up ~30%, while stockholders' deficit stands at $199.4M and actual cash at only $3.9M (pro forma $34.0M after July 2026 financings). The other filings are largely undisclosed in their enriched fields: TG-17 and AlphaVest excerpts are XBRL metadata without readable figures, so period-over-period comparisons cannot be drawn from them. Common themes are capital-raising under strain: illiquid or subordinated instruments (Phoenix), best-efforts deals with no minimum or escrow (reAlpha), and cash-burning development stage issuers (Rezera). Market implication is elevated dilution and liquidity risk across the pipeline, with the rest of the stream offering limited verifiable insight until full narrative and financial data are available.

5 high priority 5 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 21, 2026

The IPO Pipeline stream for 2026-10-21 contains three filings, all dated the same day, and only two are squarely in scope: Helio Corp /FL/ (S-1, a proposed IPO registration) and TMI Partner Holdings / CCO Holdings (S-4, a debt exchange tied to the Cox and Liberty Broadband transactions). Valley National Bancorp's S-4 for its merger with Providence Financial is a bank stock-for-cash merger registration rather than an IPO or follow-on, so it is excluded as out of scope for this themed digest. The enriched period-over-period, insider, guidance and capital allocation fields are largely unpopulated in the excerpts provided, so quantitative trend analysis is not possible from this set; signals below are limited to what the filings state. Helio's IPO is the only true pipeline event, but its financials, offering size and pricing are absent from the excerpt, making its investment case unassessable today. The CCO/Charter filing matters as a leverage story: management explicitly flags that the Cox and Liberty Broadband transactions will raise indebtedness and interest expense. The most actionable near-term item is the Helio S-1 public flip, where pricing terms and financials should emerge in subsequent amendments.

3 high priority 3 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 20, 2026

Three SEC filings dated October 20, 2026 were reviewed for the IPO Pipeline stream, which tracks new IPO registrations and follow-on offerings. Only two are clearly in scope: BioAtla's S-1 and Powerdyne's S-1 both represent capital-raising registrations, while Verizon's S-4 is a debt exchange registration rather than an IPO or follow-on offering, so it is excluded under the relevance guardrail. The enriched period-over-period, forward-looking, insider, and capital allocation fields are largely absent from the extracted text, so the quantitative trend analysis the stream calls for cannot be performed reliably. What the filings do show is a shared pattern of financing dependence: BioAtla references a Standby Equity Purchase Agreement alongside going-concern and liquidity disclosures, and Powerdyne references serial convertible promissory notes from September 2025 through May 2026 plus a July 24, 2026 equity financing agreement. Both companies therefore appear to be raising capital under distressed or dilutive conditions rather than from a position of strength. Materiality is moderate (6/10 for both in-scope filings), and the key market implication is that the registrations signal near-term supply pressure and dilution risk. Investors should treat these as financing-driven filings and verify offering size, pricing, and use of proceeds once the full prospectus text is available.

3 high priority 3 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 19, 2026

This IPO Pipeline stream covers four US SEC registration filings dated October 19, 2026, but the enriched data is thin: the two Mobility (USA) Corp S-4 filings are substantive, while the AIAI Holdings and Star Equity Holdings excerpts are almost entirely XBRL metadata with no readable offering terms, financials, or deal consideration. The dominant development is the Eaton-Dana Mobility spin-off and two-step merger (Merger Agreement dated June 10, 2026), which pairs a 9/10 materiality transaction with clear execution risk: a $158.7 million potential termination fee, unresolved permanent debt financing against bridge facilities, and multiple closing conditions including HSR clearance, NYSE listing, and Dana stockholder approval. Dana's ongoing buybacks (8,036,601 shares for about $242.0 million against a roughly $300.0 million target) increase the SpinCo Cash Payment by an estimated $301.2 million and raise combined-company leverage, so the capital structure is still moving. No period-over-period revenue, margin, or ratio data is present in the filings provided, so portfolio-level growth or margin trends cannot be quantified from this set. The AIAI Holdings and Star Equity filings should be treated as registration placeholders pending fuller excerpts rather than actionable IPO candidates.

4 high priority 4 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 16, 2026

This IPO Pipeline digest covers five US SEC S-1 registration filings dated October 15-16, 2026, spanning a crypto-treasury company, a microcap shell, an oil and gas producer, a delisted issuer using an equity line, and a sparse XBRL-only filing. No period-over-period financial figures, insider transactions, capital allocation changes, or forward-looking guidance are available in the supplied content for most filings, so quantitative trend synthesis is limited and should be treated as directional only. The most material development is AMAZE HOLDINGS, whose NYSE American suspension (September 29, 2026) and delisting (October 12, 2026) combined with a $100 million committed equity line and a Series B conversion reset toward $0.45 signal severe dilution risk. iPower's S-1 is similarly high-materiality, as digital assets, controlled-account cash and proceeds are pledged to an affiliate of its convertible note investor, leaving common holders subordinate in a default scenario amid a trailing BTC range of $57,725 to $126,279. Across the pipeline, the dominant theme is that registrations are arriving from issuers with liquidity, collateral, or listing stress rather than from clean growth IPOs. Talyxor and NOCOPI carry minimal financial content, and WhiteHawk's hedging and preferred-dividend disclosures could not be quantified from the excerpt, so investors should pull the full filings before drawing conclusions.

5 high priority 5 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 15, 2026

This IPO Pipeline stream covered a single US SEC filing on 2026-10-15, a very quiet session as noted in the stream context. The sole filing is Cashlin's Form S-1 for a self-underwritten, best-efforts offering of 10,000,000 shares at $0.10 (up to $1,000,000 gross). The company is a Wyoming corporation based in London that launched operations June 15, 2026 with three 12-month, non-renewing customer contracts worth roughly $30,000 in annual contracted revenue. Its reported sixteen-day period produced $1,315 in revenue and $711 in net income, but cash of $3,181 against $66,981 in total liabilities signals acute liquidity strain. The filing's most consequential development is the implied swing to operating losses once platform amortization of about $21,637 per year begins July 1, 2026, given the contracted revenue base. Governance and dilution considerations are also material, with founders retaining roughly 60% control if fully subscribed and up to about 85.7% if only 25% sells. Because the period-over-period and forward-looking data are thin for a company with a two-week operating history, conclusions rest mainly on the filing's disclosed risks and capital structure rather than on trend analysis across peers.

1 high priority 1 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 14, 2026

This IPO Pipeline stream covered a single US SEC filing on 2026-10-14, a very quiet session. The only filing is Tattvance Corp's S-1 for 5,000,000 shares at a fixed $0.06 per share on a self-underwritten, best-efforts, no-minimum basis. The company is a pre-revenue Wyoming development-stage digital platform for the tattoo industry, with its flagship AI Tattoo Generator not yet commercially available and its website completed only on September 3, 2026. No period-over-period comparisons exist because the company has no operating history, so there are no cross-company trends or sector aggregates to report. The central development is a control change on September 24, 2026, when the founder sold all 2,000,000 of her shares to CEO Lukasz Dziedzic, who would hold 100% if nothing sells and about 28.57% if the full offering closes. The offering can close with zero proceeds, and no market maker has committed to quote the stock. Materiality is low (4/10) and sentiment is negative, so this is a monitoring item rather than an actionable investment idea.

1 high priority 1 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 13, 2026

All four filings are Form S-1 registration statements dated October 13, 2026, spanning a small convertible-financed company, a Cayman SPAC, a Cayman SPAC-style unit offering, and an operating industrial/electronics company with an April 2026 IPO reference. None of the filings contains readable period-over-period financial figures, insider transaction data, or forward guidance in the supplied excerpts, so no quantitative YoY or QoQ trend can be verified from the enriched fields; sentiment is neutral across all four and materiality ranges from 4/10 to 6/10. The dominant portfolio theme is the SPAC and blank-check structure: two of four filings (Apex Treasury Corp II and EuroSPAC Acquisition Corp.) are shell vehicles with no operating business, so their value depends entirely on eventual target selection and redemption dynamics. The most substantive operating-company signal is Arxis, Inc., which references a serial acquisition program (four deals from 2024 to 2026) and aerospace/defense end markets, though its IPO-timing claim (April 16, 2026) needs reconciliation with an October 2026 S-1. Alternative Ballistics Corp shows heavy reliance on related-party convertible debt, a financing profile that warrants scrutiny before any allocation.

4 high priority 4 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 09, 2026

Across the 11 filings for the IPO Pipeline stream (all dated 2026-10-09 or the immediately preceding window), the dominant theme is capital formation under strain: a small-cap IPO (Simwon America), a going-concern biotech resale registration (GT Biopharma), a capital-hungry bridge-loan-funded issuer (Cyabra), a distressed warrant overhang (BIO-key), and a convertible-debt-laden filer (Specificity) all surface alongside a clinical-stage biotech IPO (Aspen Neuroscience, Bambusa) and two SPAC or M&A-driven listings (Plus Automation via Texas Ventures III; Vireo/Planet 13 and DTI/Saltire). Period-over-period comparison data is thin across this batch: several excerpts omit revenue, margin, or net income figures entirely (Simwon, Aspen, Patriot Mobile, Specificity, Plus Automation), so cross-company growth or margin comparisons cannot be made reliably and should be treated as a data gap rather than a signal. Where quantitative anchors exist, they point to dilution and financing pressure rather than growth: GT Biopharma's 1-for-25 reverse split cut shares outstanding from 45.1M to 1.8M, BIO-key's inducement repriced warrants from $10.20 to $4.06, and Cyabra is explicitly reliant on bridge and convertible financing. Insider signals are largely absent from the excerpts, so management conviction cannot be assessed from this batch. The most market-relevant developments are the Vireo/Planet 13 merger (materiality 9/10), the Plus Automation SPAC combination with redemption scenarios, and the DTI acquisition requiring a Nasdaq 5635(a) shareholder vote. Net implication: the IPO window is open for selectively credible names, but this batch skews toward financing-dependent issuers where dilution risk outweighs the offering narrative.

11 high priority 11 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 08, 2026

Two SEC filings dated October 8, 2026 fall into the IPO Pipeline / new registrations stream: an S-4 from Boundless Bio, Inc. tied to a pending merger with Seraphа Bio, Inc. (signed June 22, 2026), and an S-4 from Columbus Circle Capital Corp II (now Inflection Point Acquisition Corp. VII) for a proposed SPAC business combination with Elroy Air, Inc., an autonomous aircraft developer. Both filings are neutral in sentiment and rated 7/10 materiality, but the supplied excerpts are largely XBRL tags and header data, so the enriched period-over-period, forward-looking, insider, and capital allocation fields contain no legible dollar amounts, growth rates, or guidance figures. No cross-company margin, growth, or insider patterns can be quantified from this set. The actionable takeaway is that both transactions are registration-stage: deal economics, exchange ratios, pro forma results and shareholder vote timing must be confirmed in the full prospectuses before any position is taken. The most material development is the emergence of a de-SPAC pathway into a capital-intensive hardware sector (autonomous aircraft), which warrants monitoring of redemption levels and funding adequacy.

2 high priority 2 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 07, 2026

The IPO pipeline is active with three S-1 filings on October 7, 2026, spanning industrial automation, medical devices, and pre-clinical biotech. FireFly Automatix seeks to go public despite a high-risk profile of net losses and significant debt, including multiple 11% and 15% debentures. Centinel Spine offers a mixed outlook with no near-term dividend policy and substantial dilution risks, but benefits from a 180-day lock-up period for insiders. Salarius Pharmaceuticals (Decoy Therapeutics) is a pre-clinical biotech with limited cash ($8.0M) and no revenue, but recently raised $3.85M through warrant exercises, signaling a focus on near-term survival over growth. Across filings, period-over-period data would highlight cash burn rates, but only Salarius provides forward-looking cash runway; all three companies lack product revenue, underscoring a speculative IPO environment. No insider trading activity was reported, limiting conviction signals. The pipeline is dominated by high-risk, pre-revenue companies, suggesting investor caution is warranted.

3 high priority 3 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 06, 2026

The IPO pipeline is rapidly diversifying across sectors, with two biotech/pre-revenue debuts (Actuate Therapeutics, Pluri), a blank-check vehicle (Tang Capital Acquisition), a profitable AI-services firm with growing losses (Fusemachines), and an innovative crypto-ETF (Winklevoss Zcash ETF) – indicating a market that is accepting both high-risk, pre-commercial science and novel digital assets. A clear period-over-period red flag emerges: Fusemachines’ net loss nearly doubled from $4.4M in 2024 to $7.7M in 2025, even as it struggles with revenue concentration (58% from three customers), presenting a classic “growth at any cost” cautionary tale. The biotech cohort shows mixed signals—Actuate has zero revenue and negative working capital (only $943K), while Pluri’s filing is a secondary resale (no new capital for operations), both suggesting fragile cash positions. The Winklevoss trust, while chasing a niche crypto, carries a distinct operational risk from a recent ~50% price crash following a security vulnerability and the departure of the core development team—highlighting a sector-specific governance gap. Taken together, this pipeline reflects a risk-on environment where investors must dissect revenue quality (Fusemachines), cash runway (Actuate), security event risks (Zcash), and sponsor skin-in-the-game (Tang Capital’s 67% stake). The key portfolio-level pattern is a bifurcation: speculative biotech and crypto offerings rush to list under the JOBS Act, while more established AI-services firms like Fusemachines face increasing scrutiny over burn rates.

5 high priority 5 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 05, 2026

The IPO pipeline for October 5, 2026, is dominated by SPAC-related filings (New Iceland Arctic, Quantum Space, Tigerless Health, Welsbach Technology Metals) and two traditional IPOs (Lycia Therapeutics, Propanc Biopharma), alongside a bank merger S-4 (Equity Bancshares). A key theme is the high risk of value destruction for public shareholders in SPAC structures: Tigerless Health has no maximum redemption threshold and a dual-class structure giving 100% voting control to one insider, while New Iceland Arctic shows negative net tangible book value per share under redemption scenarios. Period-over-period data reveals deteriorating financials at Lincoln Bancorp (net loss swung to -$13.19M from -$1.207M YoY) and heavy reliance on dilutive debt at Propanc Biopharma. Lycia Therapeutics stands out as a pre-revenue biotech with promising Phase 1 data for its lead candidate LCA-0061, but no pricing details yet. The overall pipeline signals a cautious market with significant governance and financial risks embedded in the SPAC structures, while traditional IPOs remain early-stage and speculative.

7 high priority 7 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 02, 2026

On October 2, 2026, nine SEC filings revealed a dense IPO pipeline, dominated by six initial public offerings and registration statements, alongside three merger-related S-4 filings. The day’s filings signal a surge in capital formation, particularly among clinical-stage biotech (HCW Biologics, Sunshine Biopharma), early-stage technology (Vertical Data), and specialty healthcare (BioStem Technologies) companies, many of which carry high risk due to pre-revenue status, accumulated deficits, or dilution-heavy capital structures. Aggregate period-over-period data shows that the combined pro forma entity from the John Marshall Bancorp merger would have generated $74.2M in net interest income (up 111% from JMSB standalone), while HCW Biologics remains pre-revenue with an accumulated deficit of -$168.2M. Key patterns include a notable reliance on non-traditional listing methods (direct listing for Georgia Banking Co.), heavily dilutive warrant structures, and distinct geographic concentration in the mid-Atlantic and Hong Kong-based blank check SPAC. The absence of meaningful insider trading activity in these pre-public companies limits conviction signals, but forward-looking disclosures point to material catalysts—including a Phase 1 readout and a critical Nasdaq compliance decision—that frame near-term risk/reward.

9 high priority 9 total filings